Liraglutide and MACE in Patients With Diabetes and High Cardiovascular Risk

This post hoc analysis of a randomized clinical trial evaluates the association between liraglutide and total occurrences of any major adverse cardiovascular events (MACE) and expanded MACE among patients with type 2 diabetes and high risk of cardiovascular events.

Read the full article here

Related Articles